SOPHIA: A phase 3, randomized study of margetuximab (M) plus chemotherapy (CTX) vs trastuzumab (T) plus CTX in the treatment of patients with HER2+metastatic breast cancer (MBC).

被引：7
|
作者：
Rugo, Hope S.
Pegram, Mark D.
Gradishar, William John
Cortes, Javier
Curigliano, Giuseppe
Wigginton, Jon M.
Lechleider, Robert Joseph
Cardoso, Fatima
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94132 USA
[2] Stanford Sch Med, Stanford, CA 94305 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Vall Hebron Inst Oncol, Barcelona, Spain
[5] Ist Europeo Oncol, Milan, Italy
[6] MacroGen Inc, Rockville, MD USA
[7] Champalimaud Canc Ctr, Lisbon, Portugal
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS630
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS630
引用
收藏
页数：2
相关论文
共 50 条
  • [21] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [23] TRASTUZUMAB (T) TOLERABILITY AND ACTIVITY IN HER2+METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) AGED ≥65 YEARS
    Bernardi, A.
    Zucchini, G.
    Rosati, M.
    Rubino, D.
    Quercia, S.
    Cacciari, N.
    Zamagni, C.
    Martoni, A. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 102 - 102
  • [24] Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer
    Menjon-Beltran, S.
    Olivencia-Dueso, R.
    Gonzalez-Jimenez, E.
    Titos, M. J.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [25] A phase lb study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+breast cancer (MBC).
    Waks, Adrienne Gropper
    Keenan, Tanya
    Li, Tianyu
    Tayob, Nabihah
    Wulf, Gerburg M.
    Richardson, Edward T.
    Mittendorf, Elizabeth A.
    Overmoyer, Beth
    Krop, Ian E.
    Winer, Eric P.
    Van Allen, Eliezer Mendel
    Agudo, Judith
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line plus treatment of HER2+metastatic breast cancer (MBC).
    Hamilton, Erika Paige
    Yardley, Denise A.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Borges, Virginia F.
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Efficacy of vinorelbine plus trastuzumab (VT) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab (T).
    Freixinos, V.
    Sanchez-Olle, G.
    De Mattos-Arruda, L.
    Di Cosimo, S.
    Saura, C.
    Gomez, P.
    Perez-Garcia, J. M.
    Cortes, J.
    Baselga, J.
    Bellet, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] AVIATOR/ TBCRC045: A randomized phase II study of vinorelbine (N) plus trastuzumab (H) alone or combined with avelumab (A) plus /- utomilumab (U) in patients (pts) with HER2+metastatic breast cancer (MBC) (NCT03414658)
    Waks, Adrienne
    Shi, Ruichao
    Regan, Meredith
    Dang, Chau
    Santa-Maria, Cesar
    Westbrook, Kelly
    Abramson, Vandana
    Murthy, Rashmi
    Nanda, Rita
    Rugo, Hope
    Clark, Amy
    Mainor, Candace
    Dees, Claire
    Hoyos, Valentina
    Miller, Kathy
    Stringer-Reasor, Erica
    Hunter, Natasha
    Oh, Sun Young
    Demeo, Michelle
    Okpoebo, Amanda
    Elias, Erin
    Kurt, Busem
    Lin, Nancy
    Rimawi, Mothaffar
    Wolff, Antonio
    Mittendorf, Elizabeth
    Goel, Shom
    Tolaney, Sara
    Loi, Sherene
    Krop, Ian
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)
    Storniolo, A.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Stein, S.
    Ewer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 187 - 187
  • [30] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
12345